Arch Therapeutics: Arch Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023

Arch Therapeutics, Inc. reported earnings results for the first quarter ended December 31, 2023. For the first quarter, the company reported sales was USD 0.045867 million compared to USD 0.006261... Arch Therapeutics, Inc. reported earnings results for the first quarter ended December 31, 2023. For the first quarter, the company reported sales was USD 0.045867 million compared to USD 0.006261 million a year ago. Net loss was USD 2.68 million compared to USD 1.8 million a year ago. Basic loss per share from continuing operations was USD 0.57 compared to USD 1.44 a year ago. Diluted loss per share from continuing operations was USD 0.57 compared to USD 1.44 a year ago.